Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The BP share price could face a brutal reckoning in 2026

Harvey Jones is worried about the outlook for the BP share price, as the global economy struggles and experts warn…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

How on earth did Lloyds shares explode 75% in 2025?

Harvey Jones has been pleasantly surprised by the blistering performance of Lloyds shares over the last year or two. Will…

Read more »

Group of four young adults toasting with Flying Horse cans in Brazil
Investing Articles

Down 56% with a 4.8% yield and P/E of 13 – are Diageo shares a generational bargain?

When Harvey Jones bought Diageo shares he never dreamed they'd perform this badly. Now he's wondering if they're just too…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 holdings in my Stocks and Shares ISA really increase in value by 25% in 2026?

James Beard’s been looking at the 12-month share price forecasts for some of the positions in his Stocks and Shares…

Read more »

National Grid engineers at a substation
Investing Articles

2 reasons I‘m not touching National Grid shares with a bargepole!

Many private investors like the passive income prospects they see in National Grid shares. So why does our writer not…

Read more »

Number 5 foil balloon and gold confetti on black.
Investing Articles

£10,000 invested in Greggs shares 5 years ago would have generated this much in dividends…

Those who invested in Greggs shares five years ago have seen little share price growth. However, the dividends have been…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Growth Shares

Here is the Rolls-Royce share price performance for 2023, 2024, and 2025

Where will the Rolls-Royce share price be at the end of 2026? Looking at previous years might help us find…

Read more »

Investing Articles

This FTSE 250 stock could rocket 49%, say brokers

Ben McPoland takes a closer look at a market-leading FTSE 250 company that generates plenty of cash and has begun…

Read more »